Avalo Therapeutics Valuation
| AVTX Stock | USD 9.55 0.44 4.40% |
At this time, the firm appears to be overvalued. Avalo Therapeutics shows a prevailing Real Value of $4.7 per share. The current price of the firm is $9.55. Our model approximates the value of Avalo Therapeutics from analyzing the firm fundamentals such as operating margin of (51.65) %, and Return On Equity of -0.43 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Avalo Therapeutics' valuation include:
Price Book 4.9598 | Enterprise Value 23.2 M | Enterprise Value Ebitda (0.19) | Price Sales 127.4773 | Trailing PE 0.1058 |
Overvalued
Today
Please note that Avalo Therapeutics' price fluctuation is risky at this time. Calculation of the real value of Avalo Therapeutics is based on 3 months time horizon. Increasing Avalo Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Avalo Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Avalo Stock. However, Avalo Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.55 | Real 4.7 | Target 0.75 | Hype 9.69 | Naive 8.58 |
The intrinsic value of Avalo Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Avalo Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Avalo Therapeutics helps investors to forecast how Avalo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Avalo Therapeutics more accurately as focusing exclusively on Avalo Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Avalo Therapeutics' intrinsic value based on its ongoing forecasts of Avalo Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Avalo Therapeutics' closest peers.
Avalo Therapeutics Cash |
|
Avalo Valuation Trend
Analysing the historical paterns of Avalo Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Avalo Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Avalo Therapeutics Total Value Analysis
Avalo Therapeutics is presently anticipated to have valuation of 23.22 M with market capitalization of 104.53 M, debt of 537 K, and cash on hands of 11.25 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Avalo Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
23.22 M | 104.53 M | 537 K | 11.25 M |
Avalo Therapeutics Investor Information
About 65.0% of the company shares are held by institutions such as insurance companies. The book value of Avalo Therapeutics was presently reported as 2.18. The company recorded earning per share (EPS) of 94.42. Avalo Therapeutics had not issued any dividends in recent years. The entity had 1:240 split on the 29th of December 2023. Based on the key indicators related to Avalo Therapeutics' liquidity, profitability, solvency, and operating efficiency, Avalo Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Avalo Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Avalo Therapeutics has an asset utilization ratio of 9.16 percent. This suggests that the Company is making $0.0916 for each dollar of assets. An increasing asset utilization means that Avalo Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Avalo Therapeutics Ownership Allocation
The market capitalization of Avalo Therapeutics is $104.53 Million. Over half of Avalo Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Avalo Therapeutics Profitability Analysis
The company reported the previous year's revenue of 1.92 M. Net Loss for the year was (31.54 M) with loss before overhead, payroll, taxes, and interest of (7.94 M).About Avalo Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Avalo Therapeutics. We calculate exposure to Avalo Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Avalo Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 640 K | 608 K | |
| Pretax Profit Margin | (16.39) | (17.21) | |
| Operating Profit Margin | (12.19) | (12.79) | |
| Net Loss | (16.40) | (17.21) | |
| Gross Profit Margin | 0.33 | 0.35 |
Avalo Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 277.7 K |
Avalo Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Avalo Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Avalo we look at many different elements of the entity such as Avalo's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Avalo Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Avalo Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Avalo Therapeutics' worth.Additional Tools for Avalo Stock Analysis
When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.